Phase 0/I/II Cancer Prevention Clinical Trials Program Clinical Trials

Title Intervention NCT IDsort descending Sponsor Status
Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps Laboratory Biomarker Analysis, MUC1 Peptide-Poly-ICLC Vaccine, Quality-of-Life Assessment, Saline NCT02134925 National Cancer Institute (NCI) Active, not recruiting
Iloprost in Preventing Lung Cancer in Former Smokers Iloprost, Quality-of-Life Assessment, Questionnaire Administration, Placebo Administration NCT02237183 National Cancer Institute (NCI) Active, not recruiting
Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Erlotinib NCT02273362 National Cancer Institute (NCI) Active, not recruiting
Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy Telapristone Acetate, Placebo, Laboratory Biomarker Analysis, Questionnaire Administration NCT02314156 Northwestern University Active, not recruiting
PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer... Laboratory Biomarker Analysis, Rilimogene Galvacirepvec, Placebo Administration NCT02326805 National Cancer Institute (NCI) Active, not recruiting
Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful... Aspirin, Laboratory Biomarker Analysis, Placebo Administration, Questionnaire Administration NCT02521285 National Cancer Institute (NCI) Active, not recruiting
Recombinant Human Papillomavirus Nonavalent Vaccine in Preventing Human Papilloma Virus in Younger... Laboratory Biomarker Analysis, Recombinant Human Papillomavirus Nonavalent Vaccine NCT02568566 National Cancer Institute (NCI) Active, not recruiting
Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion Laboratory Biomarker Analysis, Metformin Hydrochloride NCT02581137 National Cancer Institute (NCI) Active, not recruiting
Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II... Exemestane, Laboratory Biomarker Analysis, Pharmacological Study, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration, Therapeutic Conventional Surgery NCT02598557 National Cancer Institute (NCI) Active, not recruiting
Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer Laboratory Biomarker Analysis, Nelipepimut-S Plus GM-CSF Vaccine, Sargramostim, Surgical Procedure NCT02636582 National Cancer Institute (NCI) Active, not recruiting

Pages